SG10202013038VA - Heterocyclic compound used as fgfr inhibitor - Google Patents
Heterocyclic compound used as fgfr inhibitorInfo
- Publication number
- SG10202013038VA SG10202013038VA SG10202013038VA SG10202013038VA SG10202013038VA SG 10202013038V A SG10202013038V A SG 10202013038VA SG 10202013038V A SG10202013038V A SG 10202013038VA SG 10202013038V A SG10202013038V A SG 10202013038VA SG 10202013038V A SG10202013038V A SG 10202013038VA
- Authority
- SG
- Singapore
- Prior art keywords
- compound used
- heterocyclic compound
- fgfr inhibitor
- fgfr
- inhibitor
- Prior art date
Links
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610550151.3A CN107619388A (en) | 2016-07-13 | 2016-07-13 | Heterocyclic compound as FGFR inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202013038VA true SG10202013038VA (en) | 2021-01-28 |
Family
ID=60951887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013038VA SG10202013038VA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
| SG11201900298RA SG11201900298RA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900298RA SG11201900298RA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10590109B2 (en) |
| EP (1) | EP3489223A4 (en) |
| JP (1) | JP6896852B2 (en) |
| KR (1) | KR102386428B1 (en) |
| CN (2) | CN107619388A (en) |
| AU (1) | AU2017295628B2 (en) |
| CA (1) | CA3030070A1 (en) |
| MX (1) | MX2019000451A (en) |
| PH (1) | PH12019500036A1 (en) |
| RU (1) | RU2742485C2 (en) |
| SG (2) | SG10202013038VA (en) |
| WO (1) | WO2018010514A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6941900B2 (en) * | 2017-08-04 | 2021-09-29 | アビスコ セラピューティクス カンパニー リミテッド | Aldehyde group pyridine derivative showing FGFR4 inhibitory activity, its production method and application |
| IL272838B2 (en) | 2017-10-06 | 2023-09-01 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| CN108129471A (en) * | 2018-03-20 | 2018-06-08 | 韩邦森 | A kind of synthesis technology of thiazole substituted uracil compound |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| PE20211053A1 (en) | 2018-10-05 | 2021-06-07 | Forma Therapeutics Inc | INHIBITION OF UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| CN111039874B (en) * | 2019-12-13 | 2022-11-04 | 南开大学 | Zero-wastewater preparation method of 2-amino-4-methylpyrimidine compound |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101124245B1 (en) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | Aryl carbonyl derivatives as therapeutic agents |
| CN1508130A (en) * | 2002-12-18 | 2004-06-30 | 中国科学院大连化学物理研究所 | N-phenyl-N'-pyrimidinyl-substituted urea derivative synthesizing method |
| FR2850652B1 (en) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
| PL1761520T3 (en) * | 2004-06-23 | 2008-12-31 | Lilly Co Eli | Kinase inhibitors |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| EP1790342A1 (en) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazine derivatives and their use as signal transduction modulators |
| WO2007059341A2 (en) * | 2005-11-16 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrazolothiazole protein kinase modulators |
| EP1957485B1 (en) * | 2005-12-02 | 2013-02-13 | Bayer HealthCare, LLC | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| FR2908409B1 (en) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| FR2947546B1 (en) * | 2009-07-03 | 2011-07-01 | Sanofi Aventis | PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| WO2013024427A1 (en) * | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Novel urea derivatives as tec kinase inhibitors and uses thereof |
| AU2014338549B2 (en) * | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| AU2016238436A1 (en) * | 2015-03-25 | 2017-08-17 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
-
2016
- 2016-07-13 CN CN201610550151.3A patent/CN107619388A/en active Pending
-
2017
- 2017-06-13 RU RU2019100164A patent/RU2742485C2/en active
- 2017-06-13 CA CA3030070A patent/CA3030070A1/en active Pending
- 2017-06-13 KR KR1020197004058A patent/KR102386428B1/en active IP Right Grant
- 2017-06-13 EP EP17826852.0A patent/EP3489223A4/en not_active Withdrawn
- 2017-06-13 SG SG10202013038VA patent/SG10202013038VA/en unknown
- 2017-06-13 WO PCT/CN2017/088038 patent/WO2018010514A1/en unknown
- 2017-06-13 CN CN201780002825.9A patent/CN108349896B/en active Active
- 2017-06-13 MX MX2019000451A patent/MX2019000451A/en unknown
- 2017-06-13 JP JP2019523154A patent/JP6896852B2/en active Active
- 2017-06-13 SG SG11201900298RA patent/SG11201900298RA/en unknown
- 2017-06-13 AU AU2017295628A patent/AU2017295628B2/en not_active Ceased
-
2019
- 2019-01-04 PH PH12019500036A patent/PH12019500036A1/en unknown
- 2019-01-11 US US16/246,236 patent/US10590109B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017295628A1 (en) | 2019-02-21 |
| EP3489223A4 (en) | 2020-01-15 |
| KR102386428B1 (en) | 2022-04-14 |
| CN108349896A (en) | 2018-07-31 |
| RU2019100164A (en) | 2020-08-13 |
| JP6896852B2 (en) | 2021-06-30 |
| AU2017295628B2 (en) | 2021-05-13 |
| WO2018010514A1 (en) | 2018-01-18 |
| RU2019100164A3 (en) | 2020-08-27 |
| CN107619388A (en) | 2018-01-23 |
| JP2019522055A (en) | 2019-08-08 |
| MX2019000451A (en) | 2019-09-27 |
| KR20190032420A (en) | 2019-03-27 |
| US20190144427A1 (en) | 2019-05-16 |
| EP3489223A1 (en) | 2019-05-29 |
| US10590109B2 (en) | 2020-03-17 |
| SG11201900298RA (en) | 2019-02-27 |
| CN108349896B (en) | 2021-06-01 |
| RU2742485C2 (en) | 2021-02-08 |
| CA3030070A1 (en) | 2018-01-18 |
| PH12019500036A1 (en) | 2019-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807249B (en) | Heterocyclic compound | |
| IL291099A (en) | Aminothiazole compounds as c-kit inhibitors | |
| HK1249905A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| IL263825A (en) | Heterocyclic compounds as immunomodulators | |
| HK1246794A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| EP3498706A4 (en) | Heterocyclic compound as fgfr inhibitor | |
| SI3371190T1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| IL289686A (en) | Beta-lactamase inhibitor compounds | |
| SG10202013038VA (en) | Heterocyclic compound used as fgfr inhibitor | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3483158A4 (en) | Heterocyclic compound serving as fgfr4 inhibitor | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| HK1252767A1 (en) | Pyrazol-pyridine derivatives as eaat3 inhibitors | |
| IL254890B (en) | Heterocyclic compound | |
| HK1245261A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| IL266099A (en) | Heterocyclic compound | |
| GB201621619D0 (en) | Inhibitor compounds | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors |